

MDS UK PATIENT SUPPORT GROUP

(A charitable company limited by guarantee)

Unaudited Financial Statements

Year ended 31st March 2020

Registered Company Number: 07818480

Registered Charity Number: 1145214

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March 2020

Index

Page Number	Description
3 to 12	Report of the Directors
13	Unaudited Statement of Financial Activities
14	Unaudited Balance Sheet
15 to 18	Unaudited Notes to the Financial Statements

Registered Company Number: 07818480

Registered Charity Number: 1145214

Report of the Directors for the year ended 31st March 2020

The Directors, who are also trustees, submit their report together with the financial Statements for the year ended 31st March 2020.

Results

The results for the year and the financial position of the company ("MDSUK") are shown in the annexed financial statements. The company is a non-profit distributing company limited by guarantee and is a registered charity (No, 1145214).

The financial statements have been prepared in accordance with the accounting policies and comply with the Charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard (FRS 102). The Charity has taken advantage of the exemption in Financial Reporting Standards from producing a cash flow statement on the grounds that it is entitled to the exemption for smaller companies available in Section 38 of the Companies Act 2006.

Chair's Report

The past year has been one of considerable achievement for the Charity. However, our achievements were sadly overshadowed at the end of the financial year by the effect of the Covid-19 pandemic which has placed a major burden on our financial resources.

Last year we set ourselves a number of strategic targets aimed at strengthening the Charity and broadening our range of activities for the benefit of our members. A major commitment was that of entering the field of clinical research. Such an undertaking had been discussed at length by our Central Board. A major consideration was that of finance, as sponsorship of research is extremely expensive, plus the likelihood of a positive outcome is always uncertain. Taking these factors into consideration, we decided that as it was something that many of those suffering from MDS had asked for, it was a rational way to use our financial reserves. Following the advertising of the proposed Ph.D. research, we received a number of suitable applications and after careful analysis of the proposed research, assisted by haematological clinicians, a decision was made to award the project to Queen Mary's College, Belfast University. A major reason for the award was that the research was to be based on the repair of damaged DNA, which occurs in all blood cancers. Thus, a positive outcome from the research could have significant implications for the treatment of blood cancers. A Ph.D. student was subsequently selected by the University and commenced the research in January 2020. Our Charity was congratulated by Professor Mufti (Head of Haematology at Kings College Hospital) for taking this significant step into clinical research. Unfortunately, the spread of Covid-19 has delayed the progression of the research.

With the assistance of a specialist fundraising company and following a careful analysis of our previous fundraising initiatives and that of similar Charities, a broad fundraising strategy was designed and, prior to the interruption of the pandemic, was being followed. The fundraising company also advised on the selection of a Fundraising Officer. Utilising our financial reserves, the selected individual was recruited as an employee with the objective of 'driving' the strategy.

Report of the Directors for the year ended 31st March 2020

Again, the intervention of the pandemic has severely limited the range of fundraising initiatives possible. As an example, a major fundraising event involving celebrities, at a well-known national sports location, was planned for later in the year. This, together with many of the external physical events which have been a regular source of income for us, have had to be cancelled. However, work is continuing on identifying virtual fundraising opportunities.

Following a period of improving income streams, a decision was also made to recruit additional staff as employees. The decision was based on several factors. All previous staff members had worked for the Charity on a self-employed basis, which was felt to be detrimental to the commitment, longevity and necessary learning of the individuals concerned. Two new members of staff were subsequently employed as an Office Manager and Administrative Assistant prior to the pandemic. The appointments have enabled us to make improvements in our information technology systems together with improved communication.

The expansion of our locally based support groups continued in the past year with new groups established e.g. in Kent. The pandemic has meant that Support Groups were unable to meet in person and consequently a system of virtual support groups has been devised. To some extent the greater use of meetings via media communication platforms, such as Zoom, have enabled us to expand the types of specific support offered, e.g. for carers and the bereaved, as well as those who had previously been unable to attend local support groups due to their residence in sparsely populated areas where there were no other MDS patients. We are continuing to explore the formation of additional specialist support groups to enable vital support to be offered during the ongoing lockdown. It must be remembered that Governmental easing of lockdown restrictions has little significance for MDS patients, as they remain at high risk whilst the threat of Covid-19 or Covid derivatives persist and consequently virtual meetings remain as our prime communication method.

The Charity, led by its CEO, has again played a major part in continuing to champion, lead and involve itself in organisations involved in blood cancers and rare cancers both in the United Kingdom and abroad. Our CEO has detailed our involvement in her report. Suffice it to say that MDS UK Patient Support Group continues to 'punch above its weight' both in National and International organisations in which it is involved.

Whilst the Charity has taken major decisions over the past year in order to expand and diversify, the impact of Covid has severely impacted us, probably to a greater extent than larger charities. As previously indicated, our venture into clinical research, taking on new members of staff as employees and utilising a fundraising specialist company to devise a fundraising strategy has been expensive. Our income has traditionally relied on support from those affected by MDS, who regularly undertook physical challenges throughout the year, as well as pharmaceutical grants. The pandemic has caused almost all planned external activities to be cancelled and we are having to adapt and devise new inventive ways of raising funds. However, despite the downturn in income streams occurring at an inopportune time for us, we have the necessary reserves to enable us to cover the likely deficit for the current year.

Once again, I would like to thank all those associated with MDS UK, including the members of our Board, all volunteers, patients and carers, members of staff and those within the NHS who have

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March 2020

assisted us throughout the year and without whom the Charity could not exist.

Edward Peel LL.B (Hons)
Chair MDS UK

Our purposes and activities

The Charity's principal activities during the year under review relate to the support of individuals suffering Myelodysplastic Syndrome ("MDS"), which is a rare blood cancer. The activities were previously carried on by a trust with the same name and were taken over by the company with effect from 1st April 2012.

The objects of the Charity are:

- (i) To relieve the sickness and preserve, promote and protect the health of sufferers of MDS in the United Kingdom through the provision of support, education and practical advice.
- (ii) To advance the education of the general public in the United Kingdom in all areas in relation to MDS.
- (iii) To promote and support scientific research into MDS and its treatment together with the care of MDS sufferers and those disposed to the development of MDS.

Report of the Chief Executive

Achievements and performance

The Charity's main activities are the operation and provision of the following services for individuals affected by MDS in the UK and Ireland:

- Maintaining a website with information about all aspects of MDS
- Running a telephone helpline and e-mail support
- Setting up and running regional and national group meetings at regular intervals
- Maintaining networking platforms for patients/relatives (Facebook and a chat forum)
- Maintaining other social media platforms (Twitter and Instagram)

In addition, MDS UK takes part in other related activities, to better serve and assist those affected by MDS:

- HTA – Health Technology Appraisals with NICE, SMC – to enable access to treatment
- Providing patient expertise at EMA (European Medicines Agency) level
- Participation in clinical conferences, to raise awareness of MDS and support services to haematologists and clinical staff

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March 2020

- Participation in blood cancer events, to raise awareness amongst the general public
- Participation in PPI (Patient and Public Involvement) review work at NCRI level, as well as national care and treatment guidelines for MDS.
- Patient expert and PPI reviews for clinical trials (commercial and institutions)

MDS (UK) has continued to increase its advocacy work at both UK and European levels where it affects UK issues. All of these activities provide support and information to MDS sufferers and their families.

Achievements this year included:

- MDS UK Patient Survey – initial data was accepted as a scientific poster by the main haematology conferences in UK (BSH), Europe (EHA). This survey is the largest scientifically representative sample of MDS patients in the UK and a proportion of data was analysed and presented. This work has since generated great further interest from other stakeholders, but changes in staffing, as well as the advent of COVID-19, including provisions to work from home, have prevented further work from taking place in this financial year. The remaining data will be analysed end of 2020, COVID-permitting.
- MDS World Awareness Day was marked by a successful campaign involving poetry about MDS, with contributions across the UK and the rest of the world. The MDS World Awareness Day will continue to be marked in the future, in partnership with the international MDS Alliance.
- MDS UK took part in the Make Blood Cancer Visible Campaign, to mark Blood Cancer Awareness Month in September.
- The charity concentrated on strengthening its local patient groups, which often are more convenient for elderly patients to attend. 1 further new group was created, and the potential for 4 new ones. A national patient forum event this year was not possible, due to the need to train new staff, and the advent of COVID-19. Several local meetings had to be cancelled due to COVID-19. In March 2020, MDS UK started exploring ways to implement virtual patient meetings for our members.
- The Charity has promoted its services and activities at multiple educational events throughout the UK, to groups of patients, nurses, physicians and pharma industry, through presentations and information stands.
- The start of the 3rd^d edition of the MDS Patient Handbook (in collaboration with Leukaemia CARE and Bloodwise) was postponed due to COVID-19.
- Two editions of an extended version of the MDS UK Newsletter were published, in June 2019 and March 2020, with a new Newsletter editor.

Report of the Directors for the year ended 31st March 2020


- The choice of the PhD topic was completed, with assistance of the scientific advisory board. A candidate was identified and started work – but progress was interrupted by COVID-19.
- In terms of clinical trials, MDS UK has maintained and further strengthened the level of PPI (Patient and Public Involvement) work with the NCRI MDS group of experts. A unique model of partnership was co-developed, enabling a much broader participation of patients to provide their perspectives and opinions about a new university led feasibility trial. This model of cooperation will be recommended as a future best practice model for PPI.
- MDS UK has completed the PPI review for the latest update for the National BSH (British Society of Haematology) Treatment Guidelines for MDS.
- MDS UK participated in further commercial trial reviews and research projects for pharmaceutical companies, from a PPI perspective.
- MDS UK submitted evidence for a NICE HTA in January 2020 for a new MDS drug. The HTA was subsequently cancelled, with no new date announced so far. MDS UK has been actively pursuing discussions regarding compassionate use or early access to this new drug.
- The specific Clinical Trial information service continues to be popular and accessed by patients, but also haematologists, and the Principal Investigators who can struggle to recruit rare sub-types of patients. Pharmaceutical companies have also been glad to see trial information being provided, due to slow or difficult recruitment circumstances.
- MDS UK continues to be members of various groups and umbrella organisations, including: BCA (Blood Cancer Alliance), Cancer 52, which aim to raise awareness of blood cancer issues and rare cancers respectively.
- MDS UK continued to be actively involved at European and international level through organisations such as EMA (European Medicines Agency) ESH (European School of Haematology), EHA (European Haematology Association) and ASH (American Society of Haematology), together with other MDS overseas groups. MDS Alliance activities have been maintained, with MDS UK coming to the end of its 2-year chairmanship in December 2019. MDS UK continues to lead several working groups within MDS Alliance.
- MDS UK, via the MDS Alliance, has continued to work on the European project on rare diseases called ERN's (European Reference Networks). The ERN dedicated to rare haematology conditions is called EuroBloodNet and the main purpose is to share best practice across Europe as well as facilitate cross-border healthcare and a wider access to clinical trials. However, COVID-19 has significantly slowed down progress with this project.
- Via MDS Alliance, MDS UK maintained its active contribution to the scientific public-

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March 2020

private partnership project, HARMONY, which represents a unique data-sharing collaboration across European research centres which aims to provide answers to specific unresolved research queries.

- In terms of staffing, MDS UK revised the office set-up, by directly employing personnel through PAYE. The Office Manager position has been maintained, and a dedicated Membership Officer role was created to streamline processes, due to an increased level of activities and membership level. A full-time Fundraising Officer staff member was appointed, taking over from a previous part-time volunteer. Significant training time was dedicated to new staff in early 2020. HR tasks were allocated to a committee member for the time being.
- A Fundraising Strategy was developed further, to ensure longer term sustainability of the charity and its services, however plans and progress had to be revised due to COVID-19.
- Significant revisions to the IT and database setup were implemented in late 2019, to improve work processes. However, COVID-19 forced a complete change of work practices and hardware, by having to operate remotely, as staff needed to work from home. A new IT support company was appointed for this process.
- COVID-19 significantly interfered with the end of the financial year, doubling the amount of helpline and email workload. The pandemic also forced a complete overhaul of working practices, job descriptions, and re-training of existing and new staff, to respond to the need and demand for new services being accessible virtually and remotely.



Sophie Wintrich
Chief Executive

Report of the Directors for the year ended 31st March 2020

Financial Review

The following figures were taken from the full accounts approved on October 23rd, 2020 which have been examined by an independent examiner. This part of the Trustee's annual report comments on the key features of these accounts. In this section we explain how we raised the money and then how we spent it.

Money received - £93,977. Money spent - £309,339

Overall, we ended with a deficit of £215,362 compared to a surplus of £4,895 in 2018/19.

Money received: sources of funds

Total income for the year of £93,977 was 40% lower than the previous year (2018/19- £156,179) Donations of £82,202 from members of the public and relatives of patients were similar to last year. There was no legacy income, (2018/19 £59,797). The grant of £6,500 received from Janssen was unrestricted and complied with the Code of Practice for the UK Pharmaceutical Industry

Money spent:

Expenditure for the year of £136,293 before the research grant was £14,991 less than last year. Expenditure on reimbursed staff was lower as there was a delay in replacing the seconded project worker. This was partially offset by additional expenditure on fundraising and the web site. In November last year the Directors were able to pursue the third objective of the Charity, 'to promote and support scientific research into MDS and its treatment'. A research grant to target DNA damage deficiency in MDS was made to a team at Queen's University Belfast. A commitment of £173,046 was made to fund a four - year PhD programme starting in January 2020. A provision for the full amount of the grant has been made as required by the Charities SORP (FRS 102).

The deficit for the year of £215,362 has been taken from unrestricted reserves. The previously designated £200,000 of unrestricted reserves for R&D funding has been released. Remaining unrestricted reserves at the end of the year amounted to £165,424.

Going concern

Reserves are needed to bridge the gap between the spending and receiving of income and to support the activities of the Charity in the event of a significant reduction in income. From time to time the directors review the required level of reserves. The trustees have reviewed the impact of COVID-19 on the ability of the charity to raise funds and the increase in demand for our services. The trustees have considered continued uncertainty due to Covid 19, the level of funds held, and the expected level of income and expenditure for the 12 months following the approval of these financial statements. They have concluded that the budgeted income and expenditure with the existing level of free reserves is sufficient for the Charity to be able to continue as a going concern

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March 2020

Reference and administrative details

Charity number: 1145214
Company number: 07818480
Registered Office: Haematology - Bessemer Wing (Ground Floor), Kings
College Hospital, Denmark Hill, London SE5 9RS.

Our Advisors

Examiner: David King, FCA The Dell, Old Farm Rd, Hampton, TW12 3RJ
Bankers: CAF Bank Ltd
Co-Operative Bank Ltd
CCLA Investment Management Ltd
Hampshire Trust Bank
Scottish Widows Bank Ltd
Nationwide Building Society

Directors and trustees

The directors of the charitable company (the charity) are its trustees for the purpose of charity law. The trustees serving during the year and since the year end were as follows:

Edward Peel
Sophie Wintrich
Fiona Pirilla
Don Barrett
Russell Cook
Chris Charlwood
Claudia Richards

Key management personnel:

Chief Executive: Sophie Wintrich

Report of the Directors for the year ended 31st March 2020

Structure, Governance and Management

Governing document

The entity is governed by its Memorandum and Articles of Association dated 21st October 2011. The charity is a company limited by guarantee. The members of the company who are directors are listed above. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the charity

Appointment of Directors

Existing directors propose new directors. The number of directors shall not be less than three and is not subject to any maximum.

Organisation

The board of directors administers the charity and normally meets quarterly. There is also a management committee which meets quarterly. A Chief Executive is appointed by the directors to manage the operations of the charity. To facilitate effective operations, the Chief Executive has delegated authority, within terms of delegation approved by the directors, for operational matters including finance and employment.

Equal Opportunities

The Charity operates a policy of equal opportunities. All recruitment, employment practice and service delivery within the organisation is carried out according to the principles of equal opportunities.

Risk Management

The directors have assessed the risks to which the charity is exposed and are satisfied that systems and procedures are in place to mitigate, where possible, those risks identified.

This is an especially important exercise at the current time in view of the risks surrounding COVID-19. The principal risk is that the impact on fundraising could reduce the level of activities undertaken by the charity.

Register of Interests

A register has been set up in which Directors are required to declare their outside interests, specifically directorships of other boards.

Directors' responsibilities in relation to the financial statements

The directors (who are also trustees for the purposes of charity law) are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare the financial statements for each financial year.

MDS UK PATIENT SUPPORT GROUP

Report of the Directors for the year ended 31st March 2020

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard (FRS 102) for Smaller Entities.

Under company law the directors must not approve the financial statements unless they give a true and fair view of the state of affairs of the company and of the incoming resources and outgoing resources of the company for that period

In preparing these financial statements, the directors are required to:

- (i) select suitable accounting policies and then apply them consistently;
- (ii) observe the methods and principles in the Charities Statement of Recommended Practice (SORP);
- (iii) make judgments and accounting estimates that are reasonable and prudent;
- (iv) prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping proper accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The directors are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

By Order of the board of directors



Edward Peel (Chair)

Date 13th October, 2020

Unaudited Statement of Financial Activities (Incorporating Income and Expenditure Account) for the year ended 31st March, 2020.

		2020	2019
		£	£
	Note	Total	Total
Income from			
Donations and similar incoming resources	3	82,202	88,210
Legacies	3	-	59,797
Grants	4	6,500	6,560
Investment income	5	1,766	1,612
Other Income		<u>3509</u>	<u>...</u>
Total income		<u>93,977</u>	<u>156,179</u>
Expenditure on			
Raising Funds	6	17,861	6,771
Charitable activities	7	116,927	141,711
Provision for Research grant	9	173,046	...
Governance Costs	11	<u>1505</u>	<u>2802</u>
Total expenditure		<u>309,339</u>	<u>151,284</u>
Net income		-215,362	4,895
Reconciliation of funds			
Total funds brought forward		380,786	375,891
Total funds carried forward		<u><u>165,424</u></u>	<u><u>380,786</u></u>

All amounts relate to continuing activities

The notes on pages 15 to 18 form part of these financial statements

MDS UK PATIENT SUPPORT GROUP

Unaudited Balance sheet As at 31st March 2020.

		2020 £	2019 £
	Note	Total	Total
Current assets:			
Debtors	13	4,710	10,899
Current asset investments	14	322,423	320,657
Cash at bank and in hand		34,385	55,017
Liabilities: Amounts falling due within one year			
Creditors and accruals	15	-26,800	-5,787
Total Net Assets		334,718	380,786
Provision for research grant		169,294	-
The Funds of the Charity		165,424	380,786
Unrestricted income funds	16	165,424	380,786
Total funds		165,424	380,786

For the year ending 31st March 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies and its members have not required the company to obtain an audit of its financial statements in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act in respect of accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements on pages 13 to 18 were approved by the board of directors on the 23rd October 2020 and authorised for issue and signed on its behalf by:



E Peel
Chair

Registered Company Number: 07818480
Registered Charity Number: 1145214

1) Accounting policies

The Charity is a company limited by guarantee registered in England & Wales and has no share capital. The charity's registered office address is Haematology - Bessemer Wing, Kings College Hospital, Denmark Hill, London SE5 9RS. Its registered company number is 07818480 and its charity number is 1145214.

Basis of preparation

The financial statements were prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standards applicable in the UK and Republic of Ireland (FRS 102), effective 1 January 2019 - Charities SORP (FRS 102) and the Companies Act 2006.

Assets and liabilities are recognised at historical cost or transaction value.

Preparation of accounts on a going concern basis.

The Trustees are satisfied that the company is a going concern and that these accounts should be prepared on that basis. With the continuing uncertain economic outlook the Trustees and CEO have put measures in place to extend and improve fundraising. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months following the approval of these financial statements. The budgeted income and expenditure is sufficient with the unrestricted reserves of £165,424 for the charity to continue as a going concern.

Income Recognition

Income represents income attributable to the activities of the Charity when the Charity becomes entitled to the donation or similar income and any conditions for receipt are met, and the directors are reasonably certain that they will receive it and the value can be reliably measured. Grants received without any restriction on entitlement are recognised in full upon award.

Legacy gifts are recognised following the granting of probate when the Charity has been notified in writing of both the amount and settlement date.

Donated professional services or facilities are recognised as income when the Charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of our team of volunteers is not recognised.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably. All the charity's investment income arises from money held in interest bearing deposit accounts regulated by the Prudential Regulating Authority and covered by the Government's Financial Services Compensation Scheme (FSCS).

Resources expended

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Charity to that expenditure, it is probable that settlement will be required and amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Irrecoverable VAT is reported as part of the expenditure to which it relates.

Research Grants

Grants payable are payments made to third parties in furtherance of the charitable objects of the charity. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. Provisions for grants are made where there is uncertainty as to the timing of the grant or the amount of grant payable.

Charitable activities

Costs of charitable activities includes expenditure incurred in the delivery of activities and services for beneficiaries and all the support costs as shown in note 10.

Governance costs

Governance costs comprise all costs involving public accountability of the Charity and its compliance with regulation and good practice. These costs include legal and professional fees and the costs of the AGM and governance meetings.

Corporation Tax

The Charity is considered to meet the definition of a charitable company for UK Corporation Tax purposes. Accordingly, the Charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 as any surplus or gains are applied for charitable purposes.

Reserves

The Trustees have reviewed the policy on reserves considering the uncertainties around the impact of Covid 19 on our income and expenditure in the short and medium term. The Trustees have decided to use reserves to maintain our service levels and to meet new demands to respond to Covid 19. We expect to incur a deficit of between £40,000 to £70,000 for the year ending 31 March 2021 and there will be further uncertainty for 2021/22. Any surplus reserves will be designated to promote and support scientific research into MDS.

Cash flow Statement

Due to its size, the charity is not required to present a Cash flow Statement under the Financial Reporting standards.

Unaudited notes to the financial statements as at 31st March 2020

2) Directors Remuneration

The charity reimbursed Kings College Hospital Trust for emoluments of £34,913 and pension and NI contributions of £8,648 in respect of Sophie Wintrich, the Chief Executive. The other directors neither received or waived any emoluments. The charity meets the expenses incurred by directors in carrying out their duties. During the year four directors had expenses met by the charity totaling £592 in respect of conference participation, travel and subsistence. These are included in note 7.

3) Donations, legacies and similar incoming resources.

	2020 £	2019 £
Donations (including Gift Aid)	82,202	88,210
Legacies	-	59,797
	<u>82,202</u>	<u>148,007</u>

4) Grants

Celgene Limited	-	560
Janssen	6,500	6,000
	<u>6,500</u>	<u>6,560</u>

5) Investment Income

Bank Interest Received	<u>1,766</u>	<u>1,612</u>
------------------------	--------------	--------------

6) Costs of raising funds

Advertising and promotion	4,809	2,405
Consultant	8,432	-
Event Costs	4,620	4,366
	<u>17,861</u>	<u>6,771</u>

7) Costs of activities for charitable objectives

Reimbursed staff costs	43,561	73,386
Consultant	1,250	-
Donor database development/maintenance	1,650	3,370
Website	10,540	5,964
Newsletters	26,893	21,343
Literature and Information Sheets	1,262	8,020
National Forums	-	2,689
Local Support Groups	1746	2,711
Survey	-	57
Conference Participation	1,717	4,343
Travel and expenses	355	361
Support costs (Note 10)	27,953	19,467
	<u>116,927</u>	<u>141,711</u>

Unaudited notes to the financial statements as at 31st March 2020

8) Staff Costs and Emoluments

	2020	2019
	£	£
Salaries	11,329	-
Social security costs	868	-
Pension costs	283	-
	<u>12,480</u>	<u>-</u>

9) Research Grant

Following a formal selection process Queens University Belfast was chosen to receive the first scientific research grant from the Company to improve treatment for Myelodysplastic Syndrome. The Company awarded a grant of £173,046 to fund a four year PhD programme. A total of £3752 was reimbursed covering the first quarter of 2020. A provision for the full amount of the grant has been made in accordance with the Charities SORP (FRS 102)

	2020	2019
	£	£
Support Staff	12480	-
Contract staff	9740	13030
Stationery and postage	1034	397
Telephone and broadband	1,158	1,634
Office computer and software	2,050	3,520
Recruitment	777	770
Sundry expenses	714	116
	<u>27,953</u>	<u>19,467</u>

11) Governance costs

AGM & governance meetings	1,505	1,122
Legal Fees		1,680
	<u>1,505</u>	<u>2,802</u>

12) Taxation

The company is a registered charity with no liability to tax arising in the year.

13) Debtors

Gift Aid Recoverable	1,815	1,721
Prepayments	2,700	9,178
Other	195	-
	<u>4,710</u>	<u>10,899</u>

14) Current asset investments

Nationwide Building Society Deposit	75,871	75,795
CCLA Charities Deposit	83,526	83,021
Co-Op Instant Access	64	64
Hampshire Trust	87,091	86,016
Scottish Widows Deposit	75,871	75,761
	<u>322,423</u>	<u>320,657</u>

15) Creditors

Paye	151	-
Accruals	26,649	5787
	<u>26,800</u>	<u>5,787</u>

16) Funds

Unrestricted funds of £165,424 grant		
Designated	-	200,000
Undesignated	165,424	180,786
	<u>165,424</u>	<u>380,786</u>

INDEPENDENT EXAMINERS REPORT

I report on the accounts of MDS UK PATIENT SUPPORT GROUP for the year ended 31 March 2020, which are set out on pages 13 to 18. Your attention is drawn to the fact that the charity has prepared the accounts (financial statements) in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulation that has been withdrawn.

I understand that this has been done in order to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

Respective responsibilities of directors and examiner

The directors are responsible for the preparation of the accounts. The directors consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- Examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145 (5) (b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a "true and fair view" and the report is limited to those matters set out in the statement below.


Independent examiner's statement

In connection with my examination, no matter has come to my attention:

- 1) which gives me reasonable cause to believe that in any material respect the requirements:
 - a) to keep accounting records in accordance with section 386 of the Companies Act 2006;
 - b) to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and reporting by Charities

have not been met; or

- 2) to which in my opinion attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Chartered Accountant
The Dell
Old Farm Rd
Hampton, TW12 3RJ

Date 3 November 2020